Terns Pharmaceuticals NASDAQ:TERN Chief Executive Officer Amy L. Burroughs carried out a pair of linked equity transactions on March 16, 2026, selling 14,583 shares of the company's common stock for roughly $681,108 and exercising options to acquire an identical number of shares.
The sell order was executed in two tranches. The larger tranche comprised 11,813 shares sold at a weighted average price in the range of $46.01 to $47.005 per share. A second tranche of 2,770 shares was sold at a weighted average price between $47.01 and $47.91 per share. On the same date, Burroughs exercised options to buy 14,583 shares of Terns common stock at an exercise price of $4.64 per share, for a total cost of $67,665.
Following these moves, Burroughs' direct ownership stands at 291,746 shares of TERN. She also retains an indirect stake of 8,319 shares held through the Amy L Burroughs 2017 Trust. The reported sales were executed under a pre-arranged Rule 10b5-1 trading plan that the CEO adopted on June 30, 2025.
The timing of the transactions coincides with TERN trading near its 52-week high of $48.26. The stock has recorded a steep advance over the past year, posting a 1,371% return over that period. Separately, InvestingPro analysis included with the transaction report indicates that the stock appears overvalued relative to its Fair Value. The InvestingPro note referenced additional tips and coverage available through its platform.
Market attention around Terns has also been shaped by analyst coverage and the company’s clinical progress. Leerink Partners initiated coverage with an Outperform rating and a price target of $58.00, reflecting the potential upside to that target. William Blair reiterated an Outperform rating as well, citing what it described as the "unprecedented" clinical activity of TERN-701.
TERN-701 is the company’s next-generation allosteric BCR::ABL1 inhibitor being developed for chronic myeloid leukemia. The drug’s Phase I data showed a major molecular response (MMR) rate of 64%, a result noted in the coverage and analyst commentary. That MMR figure was compared in the report to Novartis’s Scemblix, which showed a 24% rate in the cited context.
Strategically, Terns amended a license agreement with Hansoh Healthtech to assign rights to TERN-701 in several Asian markets, including mainland China and Taiwan. The amendment was presented as part of efforts to expand the drug’s regional reach through partner arrangements.
Investors and observers will likely interpret the combined insider activity, recent analyst endorsements, and the company’s clinical data through the lens of valuation and near-term market dynamics. The disclosed sale, option exercise and continued analyst interest together form the factual backdrop for current trading in TERN.
Summary
On March 16, 2026, Terns Pharmaceuticals CEO Amy L. Burroughs sold 14,583 shares for about $681,108 in two tranches while exercising options to purchase 14,583 shares at $4.64 each for $67,665. The transactions were made under a Rule 10b5-1 plan and coincided with the stock trading near its 52-week high after a 1,371% one-year gain. Analyst coverage from Leerink Partners and William Blair, plus strong Phase I results for TERN-701, have been notable recent developments. InvestingPro analysis flagged the stock as appearing overvalued relative to its Fair Value.
Key Points
- CEO transactions: Amy L. Burroughs sold 14,583 shares for approximately $681,108 and exercised options for 14,583 shares at $4.64 each (total $67,665).
- Stock context: TERN traded near a 52-week high of $48.26 after a 1,371% gain over the past year; InvestingPro flagged the stock as appearing overvalued relative to Fair Value.
- Clinical and strategic updates: Leerink and William Blair issued Outperform ratings; TERN-701 showed a 64% major molecular response rate in Phase I, and a license amendment with Hansoh Healthtech covers several Asian markets including mainland China and Taiwan.
Risks / Uncertainties
- Valuation risk - InvestingPro analysis indicates the stock currently appears overvalued relative to its Fair Value, which could pressure the share price if market sentiment shifts.
- Price volatility - The stock’s 1,371% one-year return and trading near a 52-week high suggest elevated volatility in the equity, exposing market participants to rapid price movements.
- Execution risk related to partnerships and market access - the company’s amendment to its license agreement with Hansoh Healthtech highlights reliance on strategic agreements to expand regional rights for TERN-701.